South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot

South Korea's Enzychem Lifesciences would make at least 80 million doses of India's homegrown DNA COVID-19 vaccine from Cadila Healthcare, the Indian drugmaker said on Wednesday. As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark. Cadila will get license fees and royalty payments, the company said in a filing to stock exchanges.